Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formoterol Fumarate Inhalation Solution (Perforomist) + Tiotropium in COPD
NCT00507234Phase 3Completed
- Sponsor
- Dey
- Start
- Mar 2007
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Dey. Primary endpoint: Standardized Area Under the Curve for Forced Expiratory Volume in 1 Second over 3 hours at 6 weeks. Started Mar 2007; status: completed.
02
Drugs
formoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00507234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00507234.